CN107252476A - 化合物用于治疗患者体内的cd47+癌细胞或肿瘤的用途 - Google Patents

化合物用于治疗患者体内的cd47+癌细胞或肿瘤的用途 Download PDF

Info

Publication number
CN107252476A
CN107252476A CN201710476053.4A CN201710476053A CN107252476A CN 107252476 A CN107252476 A CN 107252476A CN 201710476053 A CN201710476053 A CN 201710476053A CN 107252476 A CN107252476 A CN 107252476A
Authority
CN
China
Prior art keywords
ser
val
thr
polypeptide
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710476053.4A
Other languages
English (en)
Chinese (zh)
Inventor
王君怡
约翰·迪克
杰恩·丹斯卡
靳黎清
亚历山大·塞奥哈利德斯
苏伊萨·拉亚库玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
University Health Network
Original Assignee
Hospital for Sick Children
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43084582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107252476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital for Sick Children, University Health Network filed Critical Hospital for Sick Children
Publication of CN107252476A publication Critical patent/CN107252476A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201710476053.4A 2009-05-15 2010-05-14 化合物用于治疗患者体内的cd47+癌细胞或肿瘤的用途 Pending CN107252476A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17855309P 2009-05-15 2009-05-15
US61/178,553 2009-05-15
CN2010800213987A CN102596233A (zh) 2009-05-15 2010-05-14 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800213987A Division CN102596233A (zh) 2009-05-15 2010-05-14 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法

Publications (1)

Publication Number Publication Date
CN107252476A true CN107252476A (zh) 2017-10-17

Family

ID=43084582

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710476053.4A Pending CN107252476A (zh) 2009-05-15 2010-05-14 化合物用于治疗患者体内的cd47+癌细胞或肿瘤的用途
CN2010800213987A Pending CN102596233A (zh) 2009-05-15 2010-05-14 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800213987A Pending CN102596233A (zh) 2009-05-15 2010-05-14 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法

Country Status (15)

Country Link
US (3) US10907209B2 (enExample)
EP (3) EP4311863A3 (enExample)
JP (6) JP6091891B2 (enExample)
CN (2) CN107252476A (enExample)
AU (1) AU2010246872B2 (enExample)
CA (2) CA2983972C (enExample)
DK (2) DK2429574T3 (enExample)
ES (2) ES2539141T3 (enExample)
FI (1) FI2995315T3 (enExample)
HR (2) HRP20150553T1 (enExample)
HU (1) HUE065432T2 (enExample)
PL (2) PL2429574T3 (enExample)
PT (2) PT2995315T (enExample)
SI (2) SI2995315T1 (enExample)
WO (1) WO2010130053A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535914A (zh) * 2014-08-08 2017-03-22 阿列索治疗公司 SIRP‑α变体构建体及其用途
CN110386984A (zh) * 2018-04-17 2019-10-29 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
US11208459B2 (en) 2015-08-07 2021-12-28 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
US12527838B2 (en) 2019-11-27 2026-01-20 ALX Oncology Inc. Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
CN102643347A (zh) * 2012-03-29 2012-08-22 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hSIRPα
CN103804495A (zh) * 2012-11-07 2014-05-21 深圳大学 抗肿瘤基因工程二价类抗体及其制备方法及抗肿瘤基因工程药物
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP3311824B1 (en) * 2013-02-05 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Cd47 targeted therapies for the treatment of infectious disease
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
JP6355032B2 (ja) * 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換え二機能性融合タンパク質、それらの調製および使用
ES2751915T5 (es) 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
CN107149682B (zh) * 2016-03-04 2022-01-04 复旦大学 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
PH12018550160B1 (en) 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
WO2017177333A1 (en) * 2016-04-15 2017-10-19 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
EP3458094A4 (en) * 2016-05-19 2020-01-08 Adaerata, Limited Partnership METHOD FOR PREVENTING OR TREATING SLAMF7-POSITIVE AND SLAMF7-NEGATIVE CANCER
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
CN111511766B (zh) 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
WO2019084692A1 (en) 2017-11-06 2019-05-09 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
CN108484774B (zh) * 2018-03-09 2021-11-05 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
BR112020017709A2 (pt) * 2018-03-13 2020-12-29 Ose Immunotherapeutics Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
CN108872569A (zh) * 2018-06-19 2018-11-23 浠思（上海）生物技术有限公司 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
MX2020013068A (es) 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
CA3121273A1 (en) * 2018-11-29 2020-06-04 Trillium Therapeutics Inc. Biomarkers for cd47 blockade therapy
EP4197559A4 (en) * 2020-08-14 2024-04-24 Korea Institute of Science and Technology IMMUNOMODULATORY PROTEIN-SIRNA COMPLEX WITH ANTICANCER EFFECT
KR102398032B1 (ko) * 2020-09-22 2022-05-19 비피진 주식회사 암 치료를 위한 5''-뉴클레오티다아제 변이체
KR102557016B1 (ko) * 2020-09-22 2023-07-20 비피진 주식회사 암 치료를 위한 cd47 바인더 및 리포좀 복합체
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
WO2022229818A1 (en) 2021-04-27 2022-11-03 Pf Argentum Ip Holdings Llc Enhancement of cd47 blockade therapy with dhfr inhibitors
AU2022284373A1 (en) 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
MX2024001691A (es) * 2021-08-05 2024-04-19 Immunos Therapeutics Ag Medicamentos de combinación que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
US20250235504A1 (en) 2021-10-29 2025-07-24 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
JP2025518578A (ja) 2022-05-25 2025-06-17 ファイザー・インク がんの処置のためのｓｉｒｐアルファ融合タンパク質の投薬レジメン
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
CN120390653A (zh) 2022-12-09 2025-07-29 辉瑞大药厂 Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法
TW202440151A (zh) 2022-12-09 2024-10-16 美商輝瑞大藥廠 Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
JP2025541309A (ja) * 2022-12-15 2025-12-18 カリヴィル イムノセラピューティクス， インコーポレイテッド Ｃｄ４７／ｓｉｒｐ－アルファ免疫チェックポイント阻害剤の組成物およびその使用
CN116879560A (zh) * 2023-05-23 2023-10-13 中山大学 SIRPα抑制剂及SIRPα-Fc融合蛋白在制备治疗肿瘤的药物中的用途
WO2026062544A1 (en) 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040940A1 (en) * 1998-02-16 1999-08-19 Marie Sarfati Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
WO2009046541A1 (en) * 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0914452A2 (en) 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
US6541615B1 (en) 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1244707A1 (de) 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
JP2007008895A (ja) * 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd 抗ｃｄ４７抗体とインテグリンリガンドとの併用
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
CA2642516A1 (en) 2006-02-08 2007-08-16 Targeted Molecular Diagnostics, Llc Bivalent erbb ligand binding molecules and methods for their preparation and use
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
DE102007056623B3 (de) 2007-11-23 2009-05-20 Mtu Friedrichshafen Gmbh Verfahren zur Regelung eines stationären Gasmotors
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) † 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
BRPI0923442A2 (pt) 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040940A1 (en) * 1998-02-16 1999-08-19 Marie Sarfati Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
WO2009046541A1 (en) * 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535914A (zh) * 2014-08-08 2017-03-22 阿列索治疗公司 SIRP‑α变体构建体及其用途
CN106535914B (zh) * 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
US11208459B2 (en) 2015-08-07 2021-12-28 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US11639376B2 (en) 2015-08-07 2023-05-02 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN110386984A (zh) * 2018-04-17 2019-10-29 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN111989346A (zh) * 2018-04-17 2020-11-24 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US12527838B2 (en) 2019-11-27 2026-01-20 ALX Oncology Inc. Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer

Also Published As

Publication number Publication date
EP2429574A4 (en) 2012-10-03
US10907209B2 (en) 2021-02-02
US20190093174A1 (en) 2019-03-28
CA2761438C (en) 2017-12-12
US20120189625A1 (en) 2012-07-26
CA2761438A1 (en) 2010-11-18
SI2995315T1 (sl) 2024-05-31
HUE065432T2 (hu) 2024-05-28
EP2429574B1 (en) 2015-05-06
HRP20240362T1 (hr) 2024-06-07
JP2012526729A (ja) 2012-11-01
JP2019011347A (ja) 2019-01-24
ES2973099T3 (es) 2024-06-18
EP2429574A1 (en) 2012-03-21
JP2022180495A (ja) 2022-12-06
CA2983972A1 (en) 2010-11-18
JP2018065822A (ja) 2018-04-26
EP2995315A1 (en) 2016-03-16
JP2016029043A (ja) 2016-03-03
HRP20150553T1 (hr) 2015-08-28
EP4311863A2 (en) 2024-01-31
AU2010246872B2 (en) 2015-01-22
EP2429574B2 (en) 2026-07-22
SI2429574T1 (sl) 2015-10-30
DK2429574T3 (da) 2015-06-22
JP6254124B2 (ja) 2017-12-27
JP6410911B2 (ja) 2018-10-24
CN102596233A (zh) 2012-07-18
DK2995315T3 (da) 2024-02-19
ES2539141T3 (es) 2015-06-26
PT2429574E (pt) 2015-07-17
FI2995315T3 (fi) 2024-03-18
PL2995315T3 (pl) 2024-04-22
WO2010130053A1 (en) 2010-11-18
EP2995315B1 (en) 2023-12-27
EP4311863A3 (en) 2024-04-10
CA2983972C (en) 2023-05-02
PL2429574T3 (pl) 2015-12-31
AU2010246872A1 (en) 2011-12-01
US20240084399A1 (en) 2024-03-14
PT2995315T (pt) 2024-03-14
JP6091891B2 (ja) 2017-03-08
JP2020143146A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
US20240084399A1 (en) Compositions and methods for treating hematological cancers targeting the sirpalpha - cd47 interaction
CN107835820B (zh) 识别癌症特异性IL13Rα2的CAR T细胞
US7090843B1 (en) Recombinant anti-CD30 antibodies and uses thereof
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
CN103242444A (zh) 调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物
US8007798B2 (en) Treatment of complement-associated disorders
US20170042967A1 (en) Treatment of complement-associated disorders
JP2005521429A (ja) Ｆｃレセプターホモログ、試薬およびこれらの使用
KR20210094609A (ko) 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
CN1518458A (zh) 移植物排斥反应抑制剂
Winiarska et al. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
EP2539370B1 (en) Anti-alpha2 integrin antibodies and their uses
CN1308346C (zh) 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途
AU2022256193A1 (en) Compositions and methods for treating hematologic cancers targeting the SIRPa-CD47 interaction
KR20210070330A (ko) 혈액 종양의 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination